Project Grant R01HL187617
Award Date 8/17/26
Completion Date 5/31/31
Dollars Obligated $777K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,166 on July 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the DELE1 protein in mediating integrated stress response triggered by mitochondrial dysfunction in the heart. The research examines how DELE1 specifically activates the integrated stress response in response to mitochondrial stress—distinct from other cellular stressors—with the goal...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $721,977 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to uncover the molecular and functional organization of cardiovagal neurons that regulate heart rate through the vagus nerve. The project will map the synaptic inputs, outputs, and functional sufficiency of two distinct cardiovagal neuron subtypes—NPY2R-expressing neurons in the nucleus ambiguus and VIP-expressing neurons...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $248,999 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms regulating T-tubule structure in the mammalian heart during mechanical load conditions. The research will employ novel magnetorheological elastomer culture systems to subject isolated cardiomyocytes to pathological overload while comprehensively characterizing excitation-contraction...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $117,552 on January 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of lymphatic endothelial alpha globin in heart failure progression. The research examines how alpha globin expression in lymphatic endothelial cells mediates cardiac remodeling and chronic inflammation in cardiometabolic heart failure. Using genetically modified mice with inducible alpha globin...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $760,465 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop deep learning methods that advance cardiac magnetic resonance strain imaging for personalized cardiac resynchronization therapy treatment planning. The award funds development of deep strain networks to rapidly and accurately predict myocardial displacements from cardiac magnetic resonance imaging, addressing...
- The National Heart, Lung, and Blood Institute awarded $2.609 million to Vanderbilt University Medical Center on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the pathophysiological mechanisms of mitochondrial cyclophilin D acetylation in vascular dysfunction and hypertension through September 29, 2028. The project will define cell-specific pathogenic mechanisms of endothelial and smooth muscle cyclophilin D acetylation in hypertension and vascular...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $849,790 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode regulatory variants in cardiovascular disease through functional annotation of non-coding variants associated with CVD. The recipient will characterize non-coding regulatory variants and their mechanisms using high-throughput experimental approaches in human cardiomyocytes. Aim 1 encompasses biophysical...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...